Justin J. McAnear - Mar 19, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role: Chief Financial Officer
Signature: /s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol: TXG
Transactions as of: Mar 19, 2021
Transactions value $: -$45,707
Form type: 4
Date filed: 5/26/2021, 08:26 PM
Next filing: Jun 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXG	Class A Common Stock	Award	$0	+8.94K	+29.43%	$0.00	39.3K	Mar 19, 2021	Direct	F1, F2
transaction	TXG	Class A Common Stock	Sale	-$45.7K	-281	-0.72%	$162.66	39K	May 24, 2021	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXG	Stock Option (right to buy)	Award	$0	+22.3K		$0.00	22.3K	Mar 19, 2021	Class A Common Stock	22.3K	$177.76	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2	The number of shares beneficially owned following the reported transaction is as of March 19, 2021.
F3	These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs.
F4	The number of shares beneficially owned following the reported transaction is as of May 24, 2021.
F5	This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.